{
  "docId": "019dd923-5f69-752d-a9b6-0d0782a66fef",
  "docSlug": "GU7tHQNbAVEJiBcjPEiK",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 19,
  "pageCount": 28,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide uses a structured list format to break down key assets, clinical development history, and constraints for a competitor's product.",
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-0d0782a66fef/19",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "CLINICAL DEVELOPMENT: Mixed Phase III results submitted in 2018. Breakthrough Therapy Designation obtained. Mixed results in TRD Phase III data from 3 short-term and 2 long-term studies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3902ff23-ad3d-4c9c-901a-e8debf55ec11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "CONSTRAINTS: Uncertain efficacy and side effects limit potential future uptake. Despite mixed results, Janssen filed treatment with EMA and FDA (Q3-2018). Common adverse events include metallic taste, nausea, vertigo, dizziness, headache, dissociation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5c88666-f7dd-4e06-bd4c-0bea9ff59792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "KEY ASSETS: Same indication (TRD), significant but uncertain efficacy. Populations: 1-5 treatment failures for MDD (TRD), MDD with imminent risk of suicide (IRS). Intranasal formulation cited as differentiator.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f65d406f-7265-491d-a38a-cc6baa13c562",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "MDD = Major Depressive Disorder, SSRI = Selective Serotonin Reuptake Inhibitor. TRD co-morbidities include: muscle & joint pain (61%), anxiety & panic disorder (50%), fatigue (43%), headache/migraine (35%), sleep disorder (34%).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "921e6cf8-9ba8-4c6c-8581-33e049c7fc61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Janssen: Despite efficacy uncertainty & co-morbidities of Esketamine, company is confident about regulatory approval",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36fad5b7-01fb-42bc-b2fe-ecf0ed8db462",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 12,
      "beatId": "f8bdb5f2-d1dc-4c32-98a9-d6926ec9a7dc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 12-28 outline the development program, timeline, and team, showing a clear plan for implementation.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}